Prostate Cancer - Results from #100

Toxicity and Patient Reported QoL Outcomes Following Prostate SBRT with Focal Boost to MRI Identified Prostate Cancer Lesions: Results of a Phase II Trial. May 15, 2023

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. May 15, 2023

From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. May 15, 2023

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. May 15, 2023

Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer. May 12, 2023

Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC. May 12, 2023

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. May 12, 2023

Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy. May 12, 2023

The costs and inequities of precision medicine for patients with prostate cancer: A call to action. May 12, 2023

Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer. May 11, 2023

Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. May 11, 2023

Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy. May 11, 2023

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. May 11, 2023

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. May 11, 2023

The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer. May 11, 2023

Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. May 11, 2023

TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. May 11, 2023

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer May 10, 2023

Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study. May 10, 2023

An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation study. May 10, 2023

Page 6 of 1305